Funding for basic science, clinical studies, innovative technologies, and clinical development is available.

We believe treatment decisions should be individualized, clinically appropriate, and informed by both the available evidence and patient preferences.

The Excellence Fellowship, Judith Graham Pool Fellowship, and Sanofi-sponsored Career Development Award support multidisciplinary bleeding disorders research

The statement details reported adverse event, ongoing investigation, and plans to update the community.

The Kevin Child Scholarship is awarded annually to a student with hemophilia A or B who is either a high school senior, or someone enrolled in a vocational-technical school, college or university, or pursuing a post-secondary education.

Sutacimig is a laboratory-engineered bispecific antibody being developed as the first-ever prophylactic treatment for individuals with Glanzmann thrombasthenia.

NBDF supports efforts to ensure patients with bleeding disorders can afford life-saving medications.

Hemgenix® is an adeno-associated virus (AAV) vector-based hemophilia gene therapy product received approval by the U.S. Food and Drug Administration in November 2022.

Congress extends short-term funding while major health programs hang in the balance. Get updates on ACA tax credits, Medicaid pricing, medical debt rules, and state actions impacting the bleeding disorders community.